{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:26:14Z","timestamp":1793114774588,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40263-016-0406-8","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T09:42:09Z","timestamp":1484732529000},"page":"135-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician\u2019s Overview"],"prefix":"10.1007","volume":"31","author":[{"given":"Martin J","family":"Brodie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"406_CR1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802.","journal-title":"Lancet Neurol"},{"key":"406_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","volume":"23","author":"RJA Kinderen De","year":"2014","unstructured":"De Kinderen RJA, Evers SMAA, Rinkens R, Postulart D, Vader CI, Majdie MHJM, et al. Side effects of antiepileptic drugs: the economic burden. Seizure. 2014;23:184\u201390.","journal-title":"Seizure"},{"key":"406_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","volume":"52","author":"W Loscher","year":"2011","unstructured":"Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma. Epilepsia. 2011;52:657\u201378.","journal-title":"Epilepsia"},{"key":"406_CR4","doi-asserted-by":"publisher","unstructured":"Brodie MJ. Outcomes in newly diagnosed epilepsy in adolescents and adults: insights across a generation in Scotland. Seizure. 2016. doi: 10.1016\/j.seizure.2016.08.010 (Epub 3 Sep 2016).","DOI":"10.1016\/j.seizure.2016.08.010"},{"key":"406_CR5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","volume":"385","author":"SL Moshe","year":"2015","unstructured":"Moshe SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385:884\u201398.","journal-title":"Lancet"},{"key":"406_CR6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","volume":"42","author":"P Kwan","year":"2001","unstructured":"Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255\u201360.","journal-title":"Epilepsia"},{"key":"406_CR7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","volume":"78","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Barry SJE, Bamagous GA, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548\u201354.","journal-title":"Neurology"},{"key":"406_CR8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","volume":"20","author":"MJ Brodie","year":"2011","unstructured":"Brodie MJ, Sills GJ. Combining antiepileptic drugs: rational polytherapy? Seizure. 2011;20:369\u201375.","journal-title":"Seizure"},{"key":"406_CR9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","volume":"19","author":"MJ Brodie","year":"2010","unstructured":"Brodie MJ. Antiepileptic drug therapy: the story so far. Seizure. 2010;19:650\u20135.","journal-title":"Seizure"},{"key":"406_CR10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/9781118936979.ch54","volume-title":"The treatment of epilepsy","author":"M Holtkamp","year":"2015","unstructured":"Holtkamp M. Other less commonly used antiepileptic drugs. In: Shorvon S, Perucca E, Engel J, editors. The treatment of epilepsy. 4th ed. West Sussex: Wiley; 2015. p. 689\u2013700.","edition":"4"},{"issue":"Suppl 8","key":"406_CR11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/epi.12027","volume":"53","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Kwan P. Current position of phenobarbital and its future. Epilepsia. 2012;53(Suppl 8):40\u20136.","journal-title":"Epilepsia"},{"key":"406_CR12","first-page":"1","volume":"489","author":"World Health Organisation","year":"1972","unstructured":"World Health Organisation. International drug monitoring: the role of national centres. World Health Organ Tech Rep Ser. 1972;489:1\u201325.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"406_CR13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/epi.12681","volume":"55","author":"RT Weschler","year":"2014","unstructured":"Weschler RT, Li G, French J, O\u2019Brien TJ, D\u2019Cruz O, Williams P, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled multicenter, double-blind study. Epilepsia. 2014;55:1088\u201398.","journal-title":"Epilepsia"},{"key":"406_CR14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","volume":"68","author":"MJ Brodie","year":"2007","unstructured":"Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H, J for the Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402\u20138.","journal-title":"Neurology"},{"key":"406_CR15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yebeh.2005.01.008","volume":"6","author":"R Mohanraj","year":"2005","unstructured":"Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav. 2005;6:382\u20137.","journal-title":"Epilepsy Behav"},{"key":"406_CR16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","volume":"48","author":"G Zaccara","year":"2007","unstructured":"Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223\u201344.","journal-title":"Epilepsia"},{"key":"406_CR17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126\u201333.","journal-title":"N Engl J Med"},{"key":"406_CR18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134\u201343.","journal-title":"N Engl J Med"},{"key":"406_CR19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00023210-200317110-00002","volume":"17","author":"V Biton","year":"2003","unstructured":"Biton V. Effect of antiepileptic drugs on body weight: an overview and clinical implications for the treatment of epilepsy. CNS Drugs. 2003;17:781\u201391.","journal-title":"CNS Drugs"},{"key":"406_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11\u201327.","journal-title":"Epilepsia"},{"key":"406_CR21","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/01.WNL.0000098938.80082.25","volume":"61","author":"J McDonagh","year":"2003","unstructured":"McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology. 2003;61:1690\u20134.","journal-title":"Neurology"},{"key":"406_CR22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","volume":"334","author":"MJ Brodie","year":"1996","unstructured":"Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334:168\u201375.","journal-title":"N Engl J Med"},{"key":"406_CR23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1474-4422(12)70103-5","volume":"11","author":"T Tomson","year":"2012","unstructured":"Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803\u201313.","journal-title":"Lancet Neurol"},{"key":"406_CR24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12:244\u201352.","journal-title":"Lancet Neurol"},{"key":"406_CR25","first-page":"1907","volume":"59","author":"A Hauptmann","year":"1912","unstructured":"Hauptmann A. Luminal bei epilepsie. Munch Med Wochenschr. 1912;59:1907\u20139.","journal-title":"Munch Med Wochenschr"},{"key":"406_CR26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.0013-9580.2004.12704.x","volume":"45","author":"P Kwan","year":"2004","unstructured":"Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004;45:1141\u20139.","journal-title":"Epilepsia"},{"key":"406_CR27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.eplepsyres.2014.03.012","volume":"108","author":"P Satischandra","year":"2014","unstructured":"Satischandra P, Rao SL, Ravat S, Jayalakshsmi S, Senapathy A, Shah V, et al. The effect of phenobarbitone on cognition in adult patients with new onset epilepsy: a multi-centre prospective study from India. Epilepsy Res. 2014;108:928\u201336","journal-title":"Epilepsy Res."},{"key":"406_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.yebeh.2015.11.007","volume":"53","author":"Y Si","year":"2016","unstructured":"Si Y, Liu L, Tian L, Mu J, Chen D, Chen J, et al. A preliminary observation of the adverse effects of phenobarbital among patients with convulsive epilepsy in rural West China. Epilepsy Behav. 2016;53:65\u201370.","journal-title":"Epilepsy Behav"},{"key":"406_CR29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","volume":"68","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Besag FM, Ettinger AN, Mula M, Gobbi G, Comai S, et al. Epilepsy, antiepileptic drugs and aggression: an evidence-based review. Pharmacol Rev. 2016;68:563\u2013602.","journal-title":"Pharmacol Rev"},{"key":"406_CR30","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/epi.13509","volume":"57","author":"W Manuyakorn","year":"2016","unstructured":"Manuyakorn W, Mahasirimongkol S, Likkasittipan P, Kamchaisatian W, Wattanapokayakit S, Inunchot W, et al. Association of HLA genotypes with phenobarbital hypersensitivity in children. Epilepsia. 2016;57:1610\u20136.","journal-title":"Epilepsia"},{"key":"406_CR31","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","volume":"78","author":"S Hernandez-Diaz","year":"2012","unstructured":"Hernandez-Diaz S, Smith CL, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692\u20139.","journal-title":"Neurology"},{"key":"406_CR32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jama.1938.02790380010004","volume":"111","author":"HH Merritt","year":"1938","unstructured":"Merritt HH, Putnam TJ. Sodium diphenylhydantoin in the treatment of convulsive disorders. JAMA. 1938;111:1068\u201375.","journal-title":"JAMA"},{"key":"406_CR33","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JE, Glauser TA, Johannessen SI. Antiepileptic drugs-best practice guideline for therapeutic drug monitoring. Epilepsia. 2008;49:1239\u201376.","journal-title":"Epilepsia"},{"key":"406_CR34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1059-1311(97)80001-5","volume":"6","author":"MH Brodie","year":"1997","unstructured":"Brodie MH, Dichter MA. Established antiepileptic drugs. Seizure. 1997;6:159\u201374.","journal-title":"Seizure"},{"key":"406_CR35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","volume":"362","author":"TA Glauser","year":"2010","unstructured":"Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362:790\u20139.","journal-title":"N Engl J Med"},{"key":"406_CR36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002018-199615060-00003","volume":"15","author":"SJ Wallace","year":"1996","unstructured":"Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf. 1996;15:378\u201393.","journal-title":"Drug Saf"},{"key":"406_CR37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.seizure.2004.12.003","volume":"14","author":"EB Posner","year":"2005","unstructured":"Posner EB, Mohamed K, Marson AG. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate and lamotrigine. Seizure. 2005;14:117\u201322.","journal-title":"Seizure"},{"key":"406_CR38","first-page":"225","volume":"110","author":"C Lairy","year":"1964","unstructured":"Lairy C. Psychotic signs in epileptics during treatment with ethosuximide. Rev Neurol. 1964;110:225\u20136.","journal-title":"Rev Neurol"},{"key":"406_CR39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1527-3458.2007.00009.x","volume":"13","author":"MJ Goren","year":"2007","unstructured":"Goren MJ, Onat F. Ethosuximide: from bench to bedside. CNS Drugs Rev. 2007;13:224\u201339.","journal-title":"CNS Drugs Rev"},{"key":"406_CR40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2125.1984.tb02528.x","volume":"18","author":"W Kuhnz","year":"1984","unstructured":"Kuhnz W, Koch S, Hartmann A, Helge H, Nau N. Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentration in nursed infants and clinical status. Br J Clin Pharmacol. 1984;18:671\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"406_CR41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1528-1157.1987.tb04220.x","volume":"28","author":"GJA MacPhee","year":"1987","unstructured":"MacPhee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of auto-induction of metabolism. Epilepsia. 1987;28:286\u201394.","journal-title":"Epilepsia"},{"key":"406_CR42","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1474-4422(09)70240-6","volume":"8","author":"MJ Brodie","year":"2009","unstructured":"Brodie MJ, Elder AJ, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8:1019\u201350.","journal-title":"Lancet Neurol"},{"key":"406_CR43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","volume":"55","author":"U Amstutz","year":"2014","unstructured":"Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamara H, et al. Recommendations for HLA-B*15:02 and HLA-A* 31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55:496\u2013506.","journal-title":"Epilepsia"},{"key":"406_CR44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","volume":"10","author":"T Tomson","year":"2011","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609\u201317.","journal-title":"Lancet Neurol"},{"key":"406_CR45","first-page":"435","volume":"18","author":"H Meunier","year":"1963","unstructured":"Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M. Pharmacodynamic properties of N-dipropylacetic acid: anticonvulsive action. Therapie. 1963;18:435\u20138.","journal-title":"Therapie"},{"issue":"Suppl 9","key":"406_CR46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1528-1167.2005.00327.x","volume":"46","author":"N Hitiris","year":"2005","unstructured":"Hitiris N, Brodie MJ. Evidence based treatment of idiopathic generalized epilepsies with older antiepileptic drugs. Epilepsia. 2005;46(Suppl 9):149\u201353.","journal-title":"Epilepsia"},{"key":"406_CR47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","volume":"10","author":"E Perucca","year":"2011","unstructured":"Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446\u201356.","journal-title":"Lancet Neurol"},{"issue":"Suppl 9","key":"406_CR48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","volume":"48","author":"Menachem E Ben","year":"2007","unstructured":"Ben Menachem E. Weight issues for people with epilepsy: a review. Epilepsia. 2007;48(Suppl 9):42\u20135.","journal-title":"Epilepsia"},{"key":"406_CR49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ana.410390506","volume":"39","author":"JIT Isojarvi","year":"1996","unstructured":"Isojarvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39:579\u201384.","journal-title":"Ann Neurol"},{"key":"406_CR50","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pederson LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders or childhood autism. JAMA. 2013;309:1695\u2013703.","journal-title":"JAMA"},{"key":"406_CR51","volume-title":"Medicines related to valproate: risk of abnormal pregnancy outcomes. Drug Safety Update","author":"Medicines and Healthcare Products Regulatory Agency","year":"2015","unstructured":"Medicines and Healthcare Products Regulatory Agency. Medicines related to valproate: risk of abnormal pregnancy outcomes. Drug Safety Update. London: MHRA; 2015."},{"key":"406_CR52","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","volume":"56","author":"T Tomson","year":"2015","unstructured":"Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56:1006\u201319.","journal-title":"Epilepsia"},{"key":"406_CR53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(03)00435-6","volume":"2","author":"CJ Vecht","year":"2003","unstructured":"Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003;2:404\u20139.","journal-title":"Lancet Neurol"},{"key":"406_CR54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2005","unstructured":"Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmol. 2005;61:246\u201355.","journal-title":"Br J Clin Pharmol"},{"key":"406_CR55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1528-1157.1971.tb04928.x","volume":"12","author":"H Gastaut","year":"1971","unstructured":"Gastaut H, Courjon J, Poire R, Weber M. Treatment of status epilepticus with a new benzodiazepine more active than diazepam. Epilepsia. 1971;12:197\u2013214.","journal-title":"Epilepsia"},{"key":"406_CR56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.1976.00500050012003","volume":"33","author":"TR Browne","year":"1976","unstructured":"Browne TR. Clonazepam: a review of a new anticonvulsant drug. Arch Neurol. 1976;33:326\u201332.","journal-title":"Arch Neurol"},{"key":"406_CR57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM197810122991505","volume":"299","author":"TR Browne","year":"1978","unstructured":"Browne TR. Clonazepam. N Engl J Med. 1978;299:812\u20136.","journal-title":"N Engl J Med"},{"key":"406_CR58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eplepsyres.2016.04.003","volume":"123","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Chung S, Wade A, Quelen C, Guiraud-Dianara B, Clement F, et al. Clobazam and clonazepam use in epilepsy: results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68\u201374.","journal-title":"Epilepsy Res"},{"key":"406_CR59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.yebeh.2005.12.005","volume":"8","author":"A Grabowska-Grzb","year":"2006","unstructured":"Grabowska-Grzb A, Jedrzcejczak J, Nagansak E, Fiszer U. Risk factors for depression in people with epilepsy. Epilepsy Behav. 2006;8:411\u20137.","journal-title":"Epilepsy Behav"},{"key":"406_CR60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1528-1157.1973.tb03965.x","volume":"14","author":"TR Browne","year":"1973","unstructured":"Browne TR, Penry JK. Benzodiazepines in the treatment of epilepsy: a review. Epilepsia. 1973;14:277\u2013310.","journal-title":"Epilepsia"},{"key":"406_CR61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"RC Silva","year":"2007","unstructured":"Silva RC, Montenegro MA, Guerreiro CC, Guerreiro MM. Clobazam. Neurotherapeutics. 2007;4:138\u201344.","journal-title":"Neurotherapeutics"},{"key":"406_CR62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","volume":"26","author":"R Sankar","year":"2012","unstructured":"Sankar R. GABA (A) receptor physiology and its relationship to the mechanisms of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26:229\u201344.","journal-title":"CNS Drugs"},{"key":"406_CR63","doi-asserted-by":"crossref","unstructured":"Arya R, Anand V, Garg SK, Michael BD. Clobazam monotherapy for partial-onset or generalized-onset seizures. Cochrane Database Syst Rev. 2014;(10):CD009258.","DOI":"10.1002\/14651858.CD009258.pub2"},{"key":"406_CR64","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"Y Ng","year":"2007","unstructured":"Ng Y, Collins SD. Clobazam. Neurotherapeutics. 2007;4:138\u201344.","journal-title":"Neurotherapeutics"},{"key":"406_CR65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/cns.12399","volume":"21","author":"AC Gauthier","year":"2015","unstructured":"Gauthier AC, Mattson RH. Clobazam: A safe efficacious and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015;21:543\u20138.","journal-title":"CNS Neurosci Ther"},{"key":"406_CR66","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","volume":"26","author":"K Kosaki","year":"2004","unstructured":"Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steady-state of concentration of N-desmethylclobazam. Brain Dev. 2004;26:530\u20134.","journal-title":"Brain Dev"},{"key":"406_CR67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yebeh.2014.05.016","volume":"37","author":"D Tolbert","year":"2014","unstructured":"Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J. Withdrawal-related adverse events from clinical trials of clobazam in Lennox Gastaut syndrome. Epilepsy Behav. 2014;37:11\u20135.","journal-title":"Epilepsy Behav"},{"key":"406_CR68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J. 1997;314:180\u20131.","journal-title":"Br Med J"},{"key":"406_CR69","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","volume":"51","author":"MJ Maguire","year":"2010","unstructured":"Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51:2423\u201331.","journal-title":"Epilepsia"},{"key":"406_CR70","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/WNL.53.7.1503","volume":"53","author":"DF Levinson","year":"1999","unstructured":"Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology. 1999;53:1503\u201311.","journal-title":"Neurology"},{"key":"406_CR71","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","volume":"40","author":"AH Guberman","year":"1999","unstructured":"Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine associated rash: risk benefit comorbidities in adults and children. Epilepsia. 1999;40:985\u201391.","journal-title":"Epilepsia"},{"key":"406_CR72","doi-asserted-by":"crossref","unstructured":"Brodie MJ, Yuen AWC and the 105 study group. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 1997; 26:423\u201332.","DOI":"10.1016\/S0920-1211(96)01007-8"},{"key":"406_CR73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.18422","volume":"33","author":"IC Wong","year":"1999","unstructured":"Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037\u201342.","journal-title":"Ann Pharmacother"},{"key":"406_CR74","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1136\/bmj.e345","volume":"344","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Kwan P. Therapeutics: newer drugs for focal epilepsy in adults. Br Med J. 2012;344:e345. doi: 10.1136\/bmj.e345 .","journal-title":"Br Med J"},{"issue":"Suppl 5","key":"406_CR75","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1111\/j.1528-1157.1999.tb00917.x","volume":"40","author":"F Matsuo","year":"1999","unstructured":"Matsuo F. Lamotrigine. Epilepsia. 1999;40(Suppl 5):S30\u20136.","journal-title":"Epilepsia"},{"key":"406_CR76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0920-1211(97)00078-8","volume":"29","author":"EA Wilson","year":"1998","unstructured":"Wilson EA, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res. 1998;29:161\u20136.","journal-title":"Epilepsy Res"},{"key":"406_CR77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(98)90009-7","volume":"7","author":"M Baulac","year":"1998","unstructured":"Baulac M, Cavalcant I, Semah F, Arzimanoglou A, Porter JJ. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open observational study. Seizure. 1998;7:55\u201362.","journal-title":"Seizure"},{"key":"406_CR78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1528-1157.2000.tb00192.x","volume":"41","author":"J Ascanope","year":"2000","unstructured":"Ascanope J, Diedrich A, Dellabadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000;41:479\u201381.","journal-title":"Epilepsia"},{"key":"406_CR79","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3399\/bjgp12X653516","volume":"62","author":"BH Smith","year":"2012","unstructured":"Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J. Substance misuse of gabapentin. Br J Gen Pract. 2012;62:406\u20137.","journal-title":"Br J Gen Pract"},{"key":"406_CR80","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1528-1157.2000.tb00282.x","volume":"41","author":"LJ Stephen","year":"2000","unstructured":"Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia. 2000;41:977\u201380.","journal-title":"Epilepsia"},{"key":"406_CR81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1528-1157.2003.27402.x","volume":"44","author":"S Lee","year":"2003","unstructured":"Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, et al. The effect of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44:339\u201347.","journal-title":"Epilepsia"},{"key":"406_CR82","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1528-1157.2003.05402.x","volume":"44","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003;44:659\u201363.","journal-title":"Epilepsia"},{"key":"406_CR83","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1345\/aph.1E437","volume":"39","author":"SS Garris","year":"2005","unstructured":"Garris SS, Oles KS. Impact of topiramate on serum bicarbonate concentrations in adults. Ann Pharmacother. 2005;39:424\u20136.","journal-title":"Ann Pharmacother"},{"key":"406_CR84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9394(01)01013-3","volume":"132","author":"JT Banta","year":"2001","unstructured":"Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Opthalmol. 2001;132:112\u20134.","journal-title":"Am J Opthalmol"},{"key":"406_CR85","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00415-013-7239-x","volume":"261","author":"G Veiby","year":"2014","unstructured":"Veiby G, Daltveit AK, Engelsen BA, Gilus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579\u201388.","journal-title":"J Neurol"},{"key":"406_CR86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(97)05035-6","volume":"351","author":"JP Leach","year":"1998","unstructured":"Leach JP, Brodie MJ. Drug profile: Tiagabine. Lancet. 1998;351:203\u20137.","journal-title":"Lancet"},{"key":"406_CR87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0920-1211(98)00094-1","volume":"33","author":"IE Leppik","year":"1999","unstructured":"Leppik IE, Gram L, Deaton R. Safety of tiagabine: summary of 53 trials. Epilepsy Res. 1999;33:235\u201346.","journal-title":"Epilepsy Res"},{"key":"406_CR88","doi-asserted-by":"crossref","unstructured":"Azar NJ, Bangalore-Vittal N, Arain A, Abou-Khalil B. Tiagabine-induced stupor in patients with nonepileptic seizures: non-convulsive status epilepticus or encephalopathy? Epilepsy Behav. 2013;27:330\u20132.","DOI":"10.1016\/j.yebeh.2013.02.016"},{"key":"406_CR89","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.yebeh.2004.07.004","volume":"5","author":"D Schmidt","year":"2004","unstructured":"Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. 2004;5:627\u201335.","journal-title":"Epilepsy Behav"},{"key":"406_CR90","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi A, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial. Lancet. 2007;369:1000\u201315.","journal-title":"Lancet"},{"key":"406_CR91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0920-1211(89)90070-3","volume":"3","author":"M Dam","year":"1989","unstructured":"Dam M, Ekberg R, Loying Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3:70\u20136.","journal-title":"Epilepsy Res"},{"key":"406_CR92","first-page":"68","volume":"2","author":"K Umashankar","year":"2012","unstructured":"Umashankar K, Sandip M. Oxcarbazepine induced toxic epidermal necrolysis: a case report. J Drug Deliv Ther. 2012;2:68\u20139.","journal-title":"J Drug Deliv Ther"},{"key":"406_CR93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","volume":"88","author":"CB Chen","year":"2017","unstructured":"Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Teekayu PJ, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88:78\u201386.","journal-title":"Neurology."},{"key":"406_CR94","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000188819.45330.90","volume":"65","author":"X Dong","year":"2005","unstructured":"Dong X, Leppik IE, White J, Rarick J. Hyponatraemia from oxcarbazepine and carbamazepine. Neurology. 2005;65:1976\u20138.","journal-title":"Neurology"},{"key":"406_CR95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/WNF.0b013e3181f80bd4","volume":"33","author":"CH Lin","year":"2010","unstructured":"Lin CH, Lu CH, Wang FJ. Risk factors of oxcarbazepine induced hyponatraemia in patients with epilepsy. Clin Neuropharmacol. 2010;33:293\u20136.","journal-title":"Clin Neuropharmacol"},{"key":"406_CR96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2004.02.006","volume":"14","author":"R Mohanraj","year":"2005","unstructured":"Mohanraj R, Parker PG, Stephen LJ, Brodie MJ. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure. 2005;14:23\u20137.","journal-title":"Seizure"},{"key":"406_CR97","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2011.04.004","volume":"20","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Kelly K, Parker P, Brodie MJ. Levetiracetam monotherapy: outcomes from an epilepsy clinic. Seizure. 2011;20:554\u20137.","journal-title":"Seizure"},{"key":"406_CR98","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","volume":"61","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR, Yuen A, Liu RSN, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61:704\u20138.","journal-title":"Neurology"},{"key":"406_CR99","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","volume":"4","author":"V Dinkelacker","year":"2003","unstructured":"Dinkelacker V, Dietl T, Widman G, Lengler V, Elger C. Aggressive behaviour of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav. 2003;4:537\u201347.","journal-title":"Epilepsy Behav"},{"key":"406_CR100","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","volume":"61","author":"JR White","year":"2003","unstructured":"White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak T, et al. Discontinuation of levetiracetam because of behavioural side effects. Neurology. 2003;61:1218\u201321.","journal-title":"Neurology"},{"key":"406_CR101","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737175.2016.1179113","volume":"16","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ. Modern management of juvenile myoclonic epilepsy. Expert Rev Neurother. 2016;16:681\u20138.","journal-title":"Expert Rev Neurother"},{"key":"406_CR102","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/WNL.0b013e31827f0874","volume":"80","author":"E Mawhinney","year":"2013","unstructured":"Mawhinney E, Craig J, Morrow J. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80:400\u20135.","journal-title":"Neurology"},{"key":"406_CR103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0404.2011.01507.x","volume":"124","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Parker P, Kelly K, Wilson EA, Leach V, Brodie MJ. Adjunctive pregablin for uncontrolled partial-onset seizures: findings from a prospective audit. Acta Neurol Scand. 2011;124:142\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 6","key":"406_CR104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.0013-9580.2004.455004.x","volume":"45","author":"MJ Brodie","year":"2004","unstructured":"Brodie MJ. Pregablin as adjunctive therapy for partial seizures. Epilepsia. 2004;45(Suppl 6):19\u201327.","journal-title":"Epilepsia"},{"key":"406_CR105","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1528-1167.2006.00713.x","volume":"47","author":"I Malaga","year":"2006","unstructured":"Malaga I, Sanmarti FX. Two cases of painful gynecomastia and lower extremity pain in association with pregablin therapy. Epilepsia. 2006;47:1576\u20139.","journal-title":"Epilepsia"},{"key":"406_CR106","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.yebeh.2005.12.001","volume":"8","author":"N Hitiris","year":"2006","unstructured":"Hitiris N, Barrett JA, Brodie MJ. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav. 2006;8:418\u201321.","journal-title":"Epilepsy Behav"},{"key":"406_CR107","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2009.02381.x","volume":"5","author":"JT Kamel","year":"2010","unstructured":"Kamel JT, D\u2019Souza WJ, Cook MJ. Severe and disabling constipation: an adverse effect of pregablin. Epilepsia. 2010;5:1094\u20136.","journal-title":"Epilepsia"},{"key":"406_CR108","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","volume":"66","author":"S Schwan","year":"2010","unstructured":"Schwan S, Sundstrom A, Sternberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin: results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947\u201353.","journal-title":"Eur J Clin Pharmacol"},{"key":"406_CR109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yebeh.2010.01.016","volume":"17","author":"LJ Stephen","year":"2010","unstructured":"Stephen LJ, Kelly K, Wilson EA, Parker P, Brodie MJ. Prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav. 2010;17:455\u201360.","journal-title":"Epilepsy Behav"},{"key":"406_CR110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","volume":"26","author":"J Piedad","year":"2012","unstructured":"Piedad J, Rickards H, Besag FG, Cavana AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy. CNS Drugs. 2012;26:319\u201335.","journal-title":"CNS Drugs"},{"key":"406_CR111","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00023210-200519040-00010","volume":"19","author":"JE Frampton","year":"2005","unstructured":"Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs. 2005;19:347\u201367.","journal-title":"CNS Drugs"},{"key":"406_CR112","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1185\/030079907X210499","volume":"23","author":"S Wroe","year":"2007","unstructured":"Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23:1765\u201373.","journal-title":"Curr Med Res Opin"},{"key":"406_CR113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eplepsyres.2004.06.009","volume":"62","author":"PA Low","year":"2004","unstructured":"Low PA, James S, Peschel T, Leon R, Rothstein A. Zonisamide and associated oligohydrosis and hypothermia. Epilepsy Res. 2004;62:27\u201334.","journal-title":"Epilepsy Res"},{"key":"406_CR114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2013.11.016","volume":"31","author":"MJ Brodie","year":"2014","unstructured":"Brodie MJ, Kelly K, Stephen LJ. Prospective audits with new antiepileptic drugs: insights into population responses. Epilepsy Behav. 2014;31:73\u20136.","journal-title":"Epilepsy Behav"},{"key":"406_CR115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40263-015-0285-4","volume":"11","author":"MJ Brodie","year":"2015","unstructured":"Brodie MJ. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs. 2015;11:893\u2013904.","journal-title":"CNS Drugs"},{"key":"406_CR116","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.eplepsyres.2014.06.018","volume":"108","author":"LJ Stephen","year":"2014","unstructured":"Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive lacosamide: 5 years clinical experience. Epilepsy Res. 2014;108:1385\u201391.","journal-title":"Epilepsy Res"},{"key":"406_CR117","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","volume":"24","author":"JK Sake","year":"2010","unstructured":"Sake JK, Herbert D, Isojarvi J, Doty P, De Backer M, Davies K, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24:1055\u201367.","journal-title":"CNS Drugs"},{"key":"406_CR118","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11584860-000000000-00000","volume":"25","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy. Newly approved and developmental agents. CNS Drugs. 2011;25:89\u2013107.","journal-title":"CNS Drugs"},{"key":"406_CR119","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2165\/11594640-000000000-00000","volume":"71","author":"C Fattore","year":"2011","unstructured":"Fattore C, Perucca E. Novel medications for epilepsy. Drugs. 2011;71:2151\u201378.","journal-title":"Drugs"},{"key":"406_CR120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","volume":"89","author":"S Hebeisen","year":"2015","unstructured":"Hebeisen S, Pires N, Loureiro AI, Bonifacio MJ, Palma N, Whyment A, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122\u201335.","journal-title":"Neuropharmacology"},{"key":"406_CR121","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","volume":"54","author":"A Gil-Nagel","year":"2013","unstructured":"Gil-Nagel A, Elger C, Ben-Menachem E, Halasz P, Lopes-Lima J, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal seizures: integrated analysis of pooled data from double-blind phase III clinical trials. Epilepsia. 2013;54:98\u2013107.","journal-title":"Epilepsia"},{"key":"406_CR122","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40263-014-0182-2","volume":"28","author":"GM Keating","year":"2014","unstructured":"Keating GM. Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures. CNS Drugs. 2014;28:583\u2013600.","journal-title":"CNS Drugs"},{"key":"406_CR123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2015.03.005","volume":"29","author":"DK Gupta","year":"2015","unstructured":"Gupta DK, Bhoi SK, Kalita J, Misra UR. Hyponatraemia following esclicarbazepine therapy. Seizure. 2015;29:11\u20134.","journal-title":"Seizure"},{"key":"406_CR124","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","volume":"75","author":"MJ Brodie","year":"2010","unstructured":"Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al. Efficacy and safety of adjunctive retigabine\/ezogabine in refractory partial epilepsy. Neurology. 2010;75:1817\u201324.","journal-title":"Neurology"},{"key":"406_CR125","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","volume":"76","author":"JA French","year":"2011","unstructured":"French JA, Abou-Khalil BW, Leroy R, Yacoubian EM, Shin P, Hall S, et al. Randomized double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76:1555\u201363.","journal-title":"Neurology"},{"key":"406_CR126","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","volume":"53","author":"N Brickel","year":"2012","unstructured":"Brickel N, Gandhi P, Vanlandingham K, Hammond J, Derossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia. 2012;53:606\u201312.","journal-title":"Epilepsia"},{"key":"406_CR127","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2012.05.007","volume":"102","author":"A Gil-Nagel","year":"2012","unstructured":"Gil-Nagel A, Brodie MJ, Leroy R, Cyr T, Hall S, Castiglia M, et al. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies. Epilepsy Res. 2012;102:117\u201321.","journal-title":"Epilepsy Res"},{"key":"406_CR128","first-page":"546","volume-title":"The treatment of epilepsy","author":"MJ Brodie","year":"2015","unstructured":"Brodie MJ. Perampanel. In: Shorvon S, Perruca E, Engel J, editors. The treatment of epilepsy. 4th ed. West Sussex: Wiley; 2015. p. 546\u201354.","edition":"4"},{"key":"406_CR129","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","volume":"54","author":"BJ Steinhoff","year":"2013","unstructured":"Steinhoff BJ, Ben-Menacham E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481\u20139.","journal-title":"Epilepsia"},{"key":"406_CR130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","volume":"54","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Stephen LJ. Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy. Epilepsy Behav. 2016;54:100\u20133.","journal-title":"Epilepsy Behav"},{"key":"406_CR131","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","volume":"56","author":"AB Ettinger","year":"2015","unstructured":"Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenza A. Psychiatric and behavioural adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56:1252\u201363.","journal-title":"Epilepsia"},{"key":"406_CR132","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","volume":"133","author":"E Trinka","year":"2016","unstructured":"Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for refractory focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016;133:160\u201372.","journal-title":"Acta Neurol Scand"},{"key":"406_CR133","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","volume":"57","author":"KJ Meador","year":"2016","unstructured":"Meador KJ, Yang H, Pina-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57:243\u201351.","journal-title":"Epilepsia"},{"key":"406_CR134","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55:47\u201356.","journal-title":"Epilepsia"},{"key":"406_CR135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized double-blind, placebo-controlled trial. Epilepsia. 2014;55:57\u201366.","journal-title":"Epilepsia"},{"key":"406_CR136","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling M, Whitesides J, Liang W, Stalvey T, et al. A randomized double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890\u20138.","journal-title":"Epilepsia"},{"key":"406_CR137","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-016-0376-x","volume":"30","author":"SH Hoy","year":"2016","unstructured":"Hoy SH. Brivaracetam: a review in partial-onset (focal) seizures in patients with epilepsy. CNS Drugs. 2016;30:761\u201372.","journal-title":"CNS Drugs"},{"key":"406_CR138","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","volume":"52","author":"SL Yates","year":"2015","unstructured":"Yates SL, Fakhoury T, Lang W, Eckhardt K, Borghs S, D\u2019Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165\u20138.","journal-title":"Epilepsy Behav"},{"key":"406_CR139","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","volume":"52","author":"C Luoni","year":"2011","unstructured":"Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimerti CP, et al. Determinates of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52:2181\u201391.","journal-title":"Epilepsia"},{"key":"406_CR140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","volume":"25","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25:164\u201372.","journal-title":"Curr Opin Neurol"},{"key":"406_CR141","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","volume":"98","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res. 2012;98:194\u20138.","journal-title":"Epilepsy Res"},{"key":"406_CR142","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","volume":"16","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ. Pharmacological treatment of drug resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016;16:82. doi: 10.1007\/s11910-016-0678-x .","journal-title":"Curr Neurol Neurosci Rep."},{"key":"406_CR143","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","volume":"369","author":"P Kwan","year":"2011","unstructured":"Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;369:919\u201326.","journal-title":"N Engl J Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0406-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T15:59:45Z","timestamp":1749916785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0406-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0406-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]}}}